Navigation Links
Groupe Novasep to Acquire PharmaChem Technologies (Grand Bahama) Ltd
Date:9/18/2007

Combined Company Will Become one of the Leading Suppliers for the Life

Science Industries

POMPEY, France, September 18 /PRNewswire/ -- Groupe Novasep announced today that the company is finalizing discussions to acquire Bahamas-based PharmaChem Technologies (Grand Bahama) Ltd for an undisclosed amount.

The combination of Novasep and PharmaChem responds to their shared vision of becoming the leading global supplier for the Life Sciences industries, built upon unique synergies between these technology-driven companies.

Customers worldwide will now benefit from Novasep's top-notch R&D capabilities and innovative technologies along with PharmaChem's ample manufacturing capacity to produce smart APIs and intermediates.

"This acquisition reinforces our position of leadership as a global supplier of active molecules for the Life Sciences, produced in economical conditions as to comply with health, environment, and quality standards of the highest levels" commented Roger-Marc Nicoud, President of Group Novasep, and added "Groupe Novasep intends to continue developing PharmaChem's activities and to build synergies with our Synthesis and Process businesses".

Pietro Stefanutti, founder and President of PharmaChem will assume, in addition to his current responsibilities, the role of Chairman of the Board of the combined company while Mr. Nicoud will remain as President and Chief Executive Officer of Groupe Novasep. Mr. Stefanutti stated "We are very pleased to be joining Novasep in their quest to become the first-choice partner of the Life Sciences industries. Our commitment is to contribute and improve the health of the world's population".

PharmaChem's facility, based in Freeport, Bahamas is a cGMP compliant and FDA inspected plant with strong growth potential. This modern facility currently manufactures the leading antiretroviral API for a major Nasdaq-100 company committed to the treatment of HIV/AIDS worldwide.

Once the transaction is complete both companies will continue to operate under their current entity names and management structure.

About Groupe Novasep

With its headquarters near Nancy (in Eastern France), is a leading partner for the pharmaceutical, food, cosmetics, agrochemicals, and specialty chemicals industries through its two business segments - Novasep Process and Novasep Synthesis. Both strategic businesses are complementary organizations with skills designed to provide technically optimized and economical solutions for the life-science sector and related industries.

About PharmaChem Technologies Limited

PharmaChem Technologies (Grand Bahama) Ltd. is a privately held Bahamian company producing bulk Active Pharmaceutical Ingredients and Registered Intermediates. These products are used everyday to save lives in the whole world and make it a better place to live. PharmaChem's plant which was initially established in 1967 by Syntex Pharmaceuticals and acquired by the current owners in September 2003 is located on a 62 acre facility, of which 22 acres are currently developed, and has benefited over the years from several major upgrades making it a modern facility with an excellent cGMP history, with room for further expansion. The Freeport location gives PharmaChem Technologies a geographical position to easily supply its existing customers in the USA, and with Freeport's own deep water transhipment container port and international airport, the ability to supply customers globally.

Press contact

Groupe Novasep

Mr Jean-Marc Le Rudulier

Marketing & Communication Director

Groupe Novasep

82 Bd de la Moselle -B.P. 50

54340 Pompey - France

Tel : +33-(0)3-83-49-71-46

Mob : +33-(0)6-87-69-06-57

jean-marc.le.rudulier@novasep.com

Press contact

PharmaChem Technologies

Mr Randy Thompson

PharmaChem

West Sunrise Highway

Freeport, Grand Bahama Island

The Bahamas

Tel : +1-242-688-2511

rthompson@pharmachemtech.com


'/>"/>
SOURCE Groupe Novasep
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Rockwell Automation to acquire British process-control firm
2. Madisons PunchStock acquired by Getty Images
3. Fiserv acquires crime management software firm
4. GenTel acquires GlaxoSmithKline chip platform
5. RedPrairie to acquire fleet management software firm
6. Tushaus Computer acquires managed service business
7. RedPrairie acquires Denver software company
8. Eagle Technology acquires some synergy
9. Brady Corp. acquires Korean counterpart
10. Canadian firm acquires Silicon Logic
11. California investors acquire RedPrairie Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd.) (NASDAQ: ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... and nutritional products, today announced their collaboration to achieve the first-ever ... China to the United States ... ...
(Date:2/22/2017)... SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, ... UTHR ) today announced its financial results for ... "Our annual 2016 financial results reflect ... and earnings exceeded $700 million," said Martine Rothblatt, ... "These financial results strengthen our ability to develop ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... biotech research and development (R&D), today announced the establishment of Genedata Limited as ... Director Kevin Teburi, a recognized expert in life science informatics. Creating the UK ...
(Date:2/21/2017)... ... February 21, 2017 , ... Creation ... manufacturing solutions for original equipment manufacturers (OEMs) , today announced it has received ... third consecutive year winning in its category of electronics manufacturing services (EMS) providers ...
Breaking Biology Technology:
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):